The relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) and various cardiovascular and cerebrovascular diseases is inconsistent. However, the connection between Lp-PLA2 level and delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) remains unclear. The objective of this study was to investigate the relationships between the Lp-PLA2 levels in the early stages of aSAH and the occurrence of DCI.
The authors evaluated 114 patients with aSAH who were enrolled into a prospective observational cohort study. Serum Lp-PLA2 level at admission (D0), on the first morning (D1), and on the second morning of hospitalization (D2) were determined using commercial enzyme-linked immunosorbent assay kits. The relationship between Lp-PLA2 levels and DCI was analyzed.
Forty-three patients with aSAH (37.72%) experienced DCI. Mean serum Lp-PLA2 level decreased from 183.06 ± 61.36 μg/L at D0 (D0 vs D1, p = 0.303), to 175.32 ± 51.49 μg/L at D1 and 167.24 ± 54.10 μg/L at D2 (D0 vs D2, p = 0.040). The Lp-PLA2 level changes (D0-D1 and D0-D2) were comparable between patients with and without DCI. Multivariate model analysis revealed Lp-PLA2 level (D0) > 200 μg/L was a more significant factor of DCI compared with Lp-PLA2 (D1) and Lp-PLA2 (D2), and was a strong predictor of DCI (odds ratio [OR] 6.24, 95% confidence interval [CI] 2.05–18.94, p = 0.001) after controlling for World Federation of Neurosurgical Societies (WFNS) grade (OR 3.35, 95% CI 1.18–9.51, p = 0.023) and modified Fisher grade (OR 6.07, 95% CI 2.03–18.14, p = 0.001). WFNS grade (area under the curve [AUC] = 0.792), modified Fisher grade (AUC = 0.731), and Lp-PLA2 level (D0; AUC = 0.710) were all strong predictors of DCI. The predictive powers of WFNS grade, modified Fisher grade, and Lp-PLA2 (D0) were comparable (WFNS grade vs Lp-PLA2: p = 0.233; modified Fisher grade vs Lp-PLA2: p = 0.771). The poor-grade patients with Lp-PLA2 (D0) > 200 μg/L had significantly worse DCI survival rate than poor-grade patients with Lp-PLA2 (D0) ≤ 200 μg/L (p < 0.001).
The serum level of Lp-PLA2 was significantly elevated in patients with DCI, and decreased within the first 2 days after admission. Lp-PLA2 in the early stages of aSAH might be a novel predictive biomarker for the occurrence of DCI.
ABBREVIATIONSaSAH = aneurysmal subarachnoid hemorrhage; AUC = area under the curve; CI = confidence interval; COV = coefficient of variation; CTA = CT angiography; D0 = at admission; D1 = on the first morning of hospitalization; D2 = on the second morning of hospitalization; DCI = delayed cerebral ischemia; DSA = digital subtraction angiography; ELISA = enzyme-linked immunosorbent assay; Lp-PLA2 = lipoprotein-associated phospholipase A2; OR = odds ratio; ROC = receiver operating characteristic; WFNS = World Federation of Neurosurgical Societies.
BudohoskiKPGuilfoyleMHelmyAHuuskonenTCzosnykaMKirollosR: The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry85:1343–13532014
ChamlingBGrossSStoffel-WagnerBSchubertGAClusmannHCoburnM: Early diagnosis of delayed cerebral ischemia: possible relevance for inflammatory biomarkers in routine clinical practice?World Neurosurg104:152–1572017
ChenKWuYWangQWangJLiXZhaoZ: The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy. J Crit Care30:218.e1–218.e52015
ClaassenJBernardiniGLKreiterKBatesJDuYECopelandD: Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke32:2012–20202001
ConnollyESJrRabinsteinAACarhuapomaJRDerdeynCPDionJHigashidaRT: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke43:1711–17372012
DallmeierDKoenigW: Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a)). Best Pract Res Clin Endocrinol Metab28:281–2942014
DiringerMNBleckTPClaude HemphillJIIIMenonDShutterLVespaP: Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care15:211–2402011
DrenckhahnCBrabetzCMajorSWiesenthalDWoitzikJDreierJP: Criteria for the diagnosis of noninfectious and infectious complications after aneurysmal subarachnoid hemorrhage in DISCHARGE-1. Acta Neurochir Suppl115:153–1592013
DuanWPanYWangCWangYZhaoXWangY: Risk factors and clinical impact of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: analysis from the China National Stroke Registry. Neuroepidemiology50:128–1362018
LiDWeiWRanXYuJLiHZhaoL: Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: a systematic review and meta-analysis. Clin Chim Acta471:38–452017
RostamiEEngquistHHowellsTJohnsonURonne-EngströmENilssonP: Early low cerebral blood flow and high cerebral lactate: prediction of delayed cerebral ischemia in subarachnoid hemorrhage. J Neurosurg128:1762–17702018
SrinivasanAAggarwalAGaudihalliSMohantyMDhandapaniMSinghH: Impact of early leukocytosis and elevated high-sensitivity C-reactive protein on delayed cerebral ischemia and neurologic outcome after subarachnoid hemorrhage. World Neurosurg90:91–952016
TianYJiaHLiSWuYGuoLTanG: The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2. A systematic review and meta-analysis. Medicine (Baltimore)96:e94132017
TopbasCSwickARazaviMAndersonNLPearsonTWBystromC: Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and activity assays. Clin Chem64:697–7042018
TsaiAKSteffenBTOrdovasJMStrakaRZhouXHansonNQ: Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Transl Res158:99–1052011